TY  - JOUR

T1  - 694TiP DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

JO  - Annals of Oncology

PY  - 2020/09/01

AU  - Niazi T

AU  - Williams S

AU  - Davis ID

AU  - Stockler MR

AU  - Martin A

AU  - Bracken K

AU  - Roncolato F

AU  - McJannett M

AU  - Horvath L

AU  - Sengupta S

AU  - Hughes S et al

ED  - 

DO  - DOI: 10.1016/j.annonc.2020.08.2088

PB  - Elsevier BV

VL  - 31

SP  - S548

EP  - S549

Y2  - 2024/12/22

ER  -